<DOC>
	<DOCNO>NCT02818543</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetic profile patient active ulcerative colitis compare experience healthy volunteer .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study LYC-30937 Subjects With Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Active ulcerative colitis define Mayo endoscopy score â‰¥ 2 despite therapy . Male female age 18 75 May receive therapeutic dose oral 5amino salicylic acid compound oral corticosteroid therapy Current antitumor necrosis factor use Current immunosuppressant use ( Note : include corticosteroid use ) Subjects distal active disease ( i.e . proctitis ) Clinically significant active infection Known bleeding disorder , risk bleed hypercoagulable disorder anticoagulant require History malignancy within last 5 year except nonmelanoma skin cancer cervical carcinoma situ Clinically significant lab abnormality ( i.e . liver function abnormality , renal insufficiency , abnormal absolute neutrophil count hemoglobin ) History colon resection Any investigational therapy investigational biologics use within 8 week investigational medicinal product administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>